Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

The Journal of Dermatology ◽

10.1111/1346-8138.15173 ◽

2019 ◽

Vol 47 (2) ◽

pp. 114-120 ◽

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Ryusei Murata ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Adult Patients ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

OP0047 Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.252 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A65.2-A66 ◽

Author(s):

P. Taylor ◽

M. C. Genovese ◽

E. Keystone ◽

D. Schlichting ◽

S. Beattie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Extension Study ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

THU0197 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years

10.1136/annrheumdis-2017-eular.1166 ◽

2017 ◽

Author(s):

J Wollenhaupt ◽

J Silverfield ◽

EB Lee ◽

K Terry ◽

K Kwok ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

THU0179 Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-label, Long-term Extension up to 6 Years

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2859 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 259.1-259 ◽

Author(s):

J. Wollenhaupt ◽

J. Silverfield ◽

E.B. Lee ◽

S.P. Wood ◽

K.K. Terry ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

10.1136/annrheumdis-2018-eular.3115 ◽

2018 ◽

Author(s):

P. Nash ◽

L.C. Coates ◽

A.J. Kivitz ◽

P.J. Mease ◽

D.D. Gladman ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Interim Analysis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Extension Study ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy ◽

Download Full-text

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.12.015 ◽

2020 ◽

Vol 82 (4) ◽

pp. 823-831 ◽

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Hironobu Kaino ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-205124.71 ◽

2014 ◽

Vol 73 (Suppl 1) ◽

pp. A31.2-A31 ◽

Author(s):

Peter Taylor ◽

Mark Genovese ◽

Ed Keystone ◽

Douglas Schlichting ◽

Scott Beattie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years

10.1136/annrheumdis-2018-eular.1733 ◽

2018 ◽

Author(s):

J. Wollenhaupt ◽

J. Silverfield ◽

E. B. Lee ◽

K. Terry ◽

K. Kwok ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2017.04.875 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB224

Keyword(s):

Psoriatic Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Extension Study ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study

10.1136/annrheumdis-2017-eular.1414 ◽

2017 ◽

Author(s):

P Nash ◽

LC Coates ◽

AJ Kivitz ◽

PJ Mease ◽

DD Gladman ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Extension Study ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text